Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongjingning Granules (also known as Tongjingning Keli or marketed under the brand name Meixinqing) is an approved oral traditional Chinese medicine (TCM) formulation developed and manufactured by Wanbangde Pharmaceutical Group. It is composed of several herbal extracts, including Angelica sinensis (Danggui), Cyperus rotundus (Xiangfu), Paeonia lactiflora (Baishao), Corydalis yanhusuo (Yanhusuo), Salvia miltiorrhiza (Danshen), Melia toosendan (Chuanlianzi), Ligusticum chuanxiong (Chuanxiong), Carthamus tinctorius (Honghua), and Glycyrrhiza uralensis (Zhigancao). Tongjingning Granules is indicated for regulating menstruation and relieving pain, specifically for treating scanty or delayed menstruation and abdominal pain before or during menstruation (dysmenorrhea).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongjingning Granules.